Guardant Health, Inc.
$23.13B- Market cap
- $22.01B
- Debt
- +$1.50B
- Cash
- −$378.20M
Capital structure 94% equity / 6% debt · EV / Revenue 23.55x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: GH stock price at premium vs UIS $163.98 current versus $0.68 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at UIS's multiple
Implied fair value · at GH's multiple
Snapshot Sep 8, 2026, 2:04 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GH FY 2025 (ended Dec 31, 2025) · UIS FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 23.55x
Capital structure 21% equity / 79% debt · EV / Revenue 0.24x
GH carries the larger enterprise value at $23.13B against $468.89M; UIS trades on the lower EV / Revenue multiple (0.24x vs 23.55x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GUARDANT HEALTH, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Unisys Corp · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-15.14x
-2.48x
Net debt / EBITDA
Leverage against operating earnings
-3.04x
-1.48x
Cash and equivalents
Liquid reserves on the balance sheet
$378.20M
$413.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEOGENOMICS INC
GH vs NEO
Fulgent Genetics, Inc.
GH vs FLGT
EXACT SCIENCES CORP
GH vs EXAS
Natera, Inc.
GH vs NTRA
DXC Technology Co
GH vs DXC
Science Applications International Corp
GH vs SAIC
COGNIZANT TECHNOLOGY SOLUTIONS CORP
GH vs CTSH
GRID DYNAMICS HOLDINGS, INC.
GH vs GDYN
$1.50B
$700.50M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.